166 related articles for article (PubMed ID: 23246260)
1. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer.
Slovin SF; Kehoe M; Durso R; Fernandez C; Olson W; Gao JP; Israel R; Scher HI; Morris S
Vaccine; 2013 Jan; 31(6):943-9. PubMed ID: 23246260
[TBL] [Abstract][Full Text] [Related]
2. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
Durso RJ; Andjelic S; Gardner JP; Margitich DJ; Donovan GP; Arrigale RR; Wang X; Maughan MF; Talarico TL; Olmsted RA; Heston WD; Maddon PJ; Olson WC
Clin Cancer Res; 2007 Jul; 13(13):3999-4008. PubMed ID: 17606734
[TBL] [Abstract][Full Text] [Related]
3. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
[TBL] [Abstract][Full Text] [Related]
4. Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines.
Todorova K; Zoubak S; Mincheff M; Kyurkchiev S
Anticancer Res; 2005; 25(6C):4727-32. PubMed ID: 16334167
[TBL] [Abstract][Full Text] [Related]
5. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.
Vittes GE; Harden EL; Ottensmeier CH; Rice J; Stevenson FK
Eur J Immunol; 2011 Aug; 41(8):2447-56. PubMed ID: 21604260
[TBL] [Abstract][Full Text] [Related]
6. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system.
Lee JS; Pushko P; Parker MD; Dertzbaugh MT; Smith LA; Smith JF
Infect Immun; 2001 Sep; 69(9):5709-15. PubMed ID: 11500447
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.
Liu C; Hasegawa K; Russell SJ; Sadelain M; Peng KW
Prostate; 2009 Jul; 69(10):1128-41. PubMed ID: 19367568
[TBL] [Abstract][Full Text] [Related]
8. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo.
Medin JA; Liang SB; Hou JW; Kelley LS; Peace DJ; Fowler DH
Cancer Gene Ther; 2005 Jun; 12(6):540-51. PubMed ID: 15678150
[TBL] [Abstract][Full Text] [Related]
9. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA.
Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR
Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
Galsky MD; Eisenberger M; Moore-Cooper S; Kelly WK; Slovin SF; DeLaCruz A; Lee Y; Webb IJ; Scher HI
J Clin Oncol; 2008 May; 26(13):2147-54. PubMed ID: 18362364
[TBL] [Abstract][Full Text] [Related]
11. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice.
White LJ; Parsons MM; Whitmore AC; Williams BM; de Silva A; Johnston RE
J Virol; 2007 Oct; 81(19):10329-39. PubMed ID: 17652394
[TBL] [Abstract][Full Text] [Related]
12. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
[TBL] [Abstract][Full Text] [Related]
13. [Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer].
Zhuang ZX; Shen LQ; Shi Y; Lu X; Shi HZ
Zhonghua Nan Ke Xue; 2010 Aug; 16(8):698-704. PubMed ID: 21090344
[TBL] [Abstract][Full Text] [Related]
14. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.
Mincheff M; Tchakarov S; Zoubak S; Loukinov D; Botev C; Altankova I; Georgiev G; Petrov S; Meryman HT
Eur Urol; 2000 Aug; 38(2):208-17. PubMed ID: 10895014
[TBL] [Abstract][Full Text] [Related]
15. The therapeutic potential of a novel PSMA antibody and its IL-2 conjugate in prostate cancer.
Sugimoto Y; Hirota M; Yoshikawa K; Sumitomo M; Nakamura K; Ueda R; Niwa R; Suzawa T; Yamasaki M; Shitara K; Kato T; Nakamura K
Anticancer Res; 2014 Jan; 34(1):89-97. PubMed ID: 24403448
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Venezuelan equine encephalitis replicon particles packaged in different coats.
Kamrud KI; Alterson KD; Andrews C; Copp LO; Lewis WC; Hubby B; Patel D; Rayner JO; Talarico T; Smith JF
PLoS One; 2008 Jul; 3(7):e2709. PubMed ID: 18628938
[TBL] [Abstract][Full Text] [Related]
17. Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.
Cecil C; West A; Collier M; Jurgens C; Madden V; Whitmore A; Johnston R; Moore DT; Swanstrom R; Davis NL
Virology; 2007 Jun; 362(2):362-73. PubMed ID: 17275057
[TBL] [Abstract][Full Text] [Related]
18. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
Knight D; Peterson AC; Rini BI; Harlin H; Gajewski TF; Stadler WM
Prostate; 2009 Feb; 69(2):142-8. PubMed ID: 18942640
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.
Weber JS; Vogelzang NJ; Ernstoff MS; Goodman OB; Cranmer LD; Marshall JL; Miles S; Rosario D; Diamond DC; Qiu Z; Obrocea M; Bot A
J Immunother; 2011 Sep; 34(7):556-67. PubMed ID: 21760528
[TBL] [Abstract][Full Text] [Related]
20. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques.
Chen L; Ewing D; Subramanian H; Block K; Rayner J; Alterson KD; Sedegah M; Hayes C; Porter K; Raviprakash K
J Virol; 2007 Nov; 81(21):11634-9. PubMed ID: 17715224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
